Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Molecular and Cellular Biology, Genetics

Abstract 2358: Impact of MDM2 inhibition on cell cycle regulation through Aurora Kinase B - CDK1 axis in prostate cancer cells

Thanigaivelan Kanagasabai, Khalid Alhazzani, Thiagarajan Venkatesan, Sivanesan Dhandayuthapani, Ali Alaseem and Appu Rathinavelu
Thanigaivelan Kanagasabai
Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khalid Alhazzani
College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thiagarajan Venkatesan
Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivanesan Dhandayuthapani
Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Alaseem
College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Appu Rathinavelu
Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2017-2358 Published July 2017
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Abstract

Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression and therefore overexpression of CDKs contributes to the proliferation of cancer cells. A variety of genetic and epigenetic events cause over activity of the CDKs in human cancers, and their inhibition can lead to cell cycle arrest and apoptosis. In malignant cells, both elevated expression of CDKs and their modulators including cyclins, and loss of expression of CDK inhibitors result in deregulated CDK activity, providing a selective growth advantage for cancer progression. In this respect, the multifunctional mouse double minute 2 homolog (MDM2) oncoprotein has been gaining a significant amount of attention towards better understanding the cell cycle regulatory mechanisms. It is well established that MDM2 gene amplification can occur in diverse human malignancies including prostate cancer. Also, MDM2 oncoprotein has been shown to exert both p53-dependent and p53-independent roles in oncogenesis. It has been well established in several laboratories, including ours, that overexpression of MDM2, can eventually lead to the inactivation of cell cycle control and loss of apoptotic ability in many tumors. However, the mechanisms underlying the regulation of CDK1 by MDM2 in cancer cells have not been fully identified. Therefore, the main objective of our study was to understand the impact of MDM2 overexpression on CDK1 that regulates cell cycle progression and apoptosis. Our preliminary data from human cell cycle PCR array experiments revealed the expression profile of genes that are involved in different phases of cell cycle regulation in LNCaP-MST cells with and without nutlin-3 treatment. Our study clearly demonstrated a significant increase in the expression level of Aurora Kinase B (AURKB), CDC25C and CDK1 in MDM2 transfected LNCaP-MST cells as compared with non-transfected LNCaP cells. However, after treating the cells with 20 µM of MDM2 specific inhibitor nutlin-3, for 24 h, the expression levels of the above mentioned proteins were significantly altered when compared to untreated controls. In addition, inhibition of MDM2 with nutlin-3 leads to increased expression of pro-apoptotic proteins p53, p21, and Bax. Our results offer significant evidence towards the effectiveness of MDM2 inhibition in causing cell cycle arrest via blocking the transmission of signals through AURKB-CDK1 axis and inducing apoptosis in cancer cells. It is clearly evident from our data that MDM2 overexpression probably is the primary cause for CDK1 up-regulation in the LNCaP-MST cells, which might have occurred possibly through activation of AURKB. However, further studies in this direction should shed more light on the intracellular mechanisms involved in the regulation of CDK1 in MDM2 positive cancers. (This project was supported by The Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).

Citation Format: Thanigaivelan Kanagasabai, Khalid Alhazzani, Thiagarajan Venkatesan, Sivanesan Dhandayuthapani, Ali Alaseem, Appu Rathinavelu. Impact of MDM2 inhibition on cell cycle regulation through Aurora Kinase B - CDK1 axis in prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2358. doi:10.1158/1538-7445.AM2017-2358

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 77 (13 Supplement)
July 2017
Volume 77, Issue 13 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 2358: Impact of MDM2 inhibition on cell cycle regulation through Aurora Kinase B - CDK1 axis in prostate cancer cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 2358: Impact of MDM2 inhibition on cell cycle regulation through Aurora Kinase B - CDK1 axis in prostate cancer cells
Thanigaivelan Kanagasabai, Khalid Alhazzani, Thiagarajan Venkatesan, Sivanesan Dhandayuthapani, Ali Alaseem and Appu Rathinavelu
Cancer Res July 1 2017 (77) (13 Supplement) 2358; DOI: 10.1158/1538-7445.AM2017-2358

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 2358: Impact of MDM2 inhibition on cell cycle regulation through Aurora Kinase B - CDK1 axis in prostate cancer cells
Thanigaivelan Kanagasabai, Khalid Alhazzani, Thiagarajan Venkatesan, Sivanesan Dhandayuthapani, Ali Alaseem and Appu Rathinavelu
Cancer Res July 1 2017 (77) (13 Supplement) 2358; DOI: 10.1158/1538-7445.AM2017-2358
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology, Genetics

  • Abstract LB-323: Comparative miRNA microarray profiling indicates miR-363 promotes chemoresistance in ovarian cancer cells by targeting the Hippo member, LATS2
  • Abstract LB-268: Rate of temporal citrate efflux from malignant mitochondria predicts clinical aggressiveness in breast tumors
  • Abstract LB-324: Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness via targeting GRB7
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-328: Mir-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44
  • Abstract LB-331: Advanced DNA-gold nanoprobe-based direct and sensitive quantification of novel microRNAs in prostate cancer
  • Abstract LB-336: Specific serine phosphorylation of IRE-1 controls enhanced splicing of XBP-1 and regulated IRE-1-dependent decay (RIDD)
Show more 3

Poster Presentations - CDKs and CDK Inhibitors

  • Abstract 2355: Palbociclib enhances the antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating hypoxia in squamous cell lung cancer
  • Abstract 2357: CDK4/6 inhibition in early stage triple negative breast cancer
  • Abstract 2354: Identification of CDK1 as an aspirin and salicylic acid binding protein: a potential role in chemoprevention
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement